Vyriad, Inc. has announced an expansion of a Phase 1 trial at Mayo Clinic for patients with peripheral T-cell lymphoma (PTCL) using Voyager-V1 therapy after encouraging initial results. Regeneron Pharmaceuticals is co-developing the investigational therapy to treat patients with recurrent or treatment resistant cancers by dissolving cancer cells and stimulating the patient's immune system to prevent recurrence. The first-line therapies for PTCL can be curative, but most patients will experience a recurrence of the disease. Vyriad is developing virus-based therapeutics for the treatment of cancers with significant unmet needs.
Vyriad's CEO and chief scientific officer Stephen J. Russell stated that "Early Phase 1 results offered an indication that a single infusion of Voyager-V1 has the potential to provide significant benefit to patients with PTCL, a cancer with a generally poor prognosis." Participating in the trial are Mayo Clinic Rochester and Mayo Clinic Arizona while funding comes from Regeneron, National Institutes of Health, and Vyriad.
Vyriad, T-cell Lymphoma Trial, Mayo Clinic, Voyager-V1 Therapy, Recurrent Cancer